Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19

Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities

(2020) Puja Mehta et al.   Lancet Respiratory Medicine

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

(2020) Sophie Hue et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study

(2020) Zelalem Temesgen et al.   MAYO CLINIC PROCEEDINGS

High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study

(2018) Huihuang Huang et al.   Cellular & Molecular Immunology

GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation

(2016) Burkhard Becher et al.   IMMUNITY

STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation

(2014) Wanqiang Sheng et al.   CELL RESEARCH

Persistent inflammation and immunosuppression

(2012) Lori F. Gentile et al.   Journal of Trauma and Acute Care Surgery

The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF

(2011) Mohamed El-Behi et al.   NATURE IMMUNOLOGY

Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome

(2010) Mark W. Hall et al.   INTENSIVE CARE MEDICINE

Granulocyte–Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression

(2009) Christian Meisel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE